Michelle A. Booden is Director, Business Development and Licensing in the Pacific Hub for Merck & Co., Inc. and is based in San Francisco. Dr. Booden leads identification of external opportunities from discovery to preclinical proof of concept in therapeutic areas of Immunology, Infectious Diseases and Vaccines, and Oncology. Prior to Merck, Michelle held roles of increasing responsibility at the Salk Institute for Biological Studies. She was also a co-founder of Trek Therapeutics, a life sciences company developing small molecule therapeutics for patients with genetic mitochondrial diseases and NXT Biologics, which is developing vaccines and therapeutics for invasive fungal infections. Michelle also held licensing and business development appointments with the National Institutes of Health Office of Technology Transfer and the University of Pittsburgh Office of Technology Management.
Michelle earned her BS degree in Chemistry from George Mason University and PhD from the Iowa State University in biochemistry and cell biology. She completed her post-doctoral training at the University of North Carolina at Chapel Hill in the Linberger Comprehensive Cancer Center and is also a registered patent agent with the U.S. PTO.